Abstract: The present disclosure relates to compositions comprising gymnemic acid, together with a form of zinc to block the unpleasant bitter taste of gymnemic acid as well as to extend the sweet taste blocking properties of gymnemic acid, resulting in palatable compositions for delivery to the oral cavity to block sweet taste receptors located therein. The present disclosure also relates to methods of reducing sugar consumption and reducing calorie intake via administration of such compositions to a subject.

Abstract: The presently invention relates to methods, formulations and kits comprising deuterated trehalose for treating myopathies, neurodegenerative disorders, or tauopathies associated abnormal protein aggregation.

Abstract: A topical water-in-oil composition of ivermectin is provided. The topical water-in-oil composition contains an oily phase, an aqueous phase and a surfactant emulsifier. The emulsion is essentially devoid of any glycols.

Abstract: A topical oil-in-water composition of ivermectin is provided. The topical oil-in-water composition contains an oily phase, an aqueous phase and a surfactant emulsifier. The emulsion is essentially devoid of any solvents or propenetrating agents for ivermectin and any gelling agent.

Abstract: A topical lotion composition of ivermectin is provided. The topical lotion composition contains a pharmaceutically acceptable alcohol and a pharmaceutically acceptable gelling agent. The composition is essentially devoid of any surfactant.

Abstract: A topical gel composition of ivermectin is provided. The topical gel composition contains a pharmaceutically acceptable glycol and a pharmaceutically acceptable gelling agent. The composition is essentially devoid of any alcohol.

Abstract: A topical solution composition of ivermectin is provided. The topical solution composition contains a pharmaceutically acceptable alcohol and a pharmaceutically acceptable gelling agent. The composition is essentially devoid of any glycols, glycerine or ether and esters thereof.

Abstract: A naringin composition and preparations thereof are provided. The pharmaceutical composition comprises naringin and levocetirizine hydrochloride, and preferably, 27.5-275 mg of naringin and 1.25-12.5 mg of levocetirizine hydrochloride, where the preferred weight ratio of naringin to levocetirizine hydrochloride is 20:1. The pharmaceutical composition has good curative effects on cough and sputum production originating from various causes and on cough variant asthma. The efficacy of the pharmaceutical composition is obviously superior to that of naringin or levocetirizine hydrochloride that is used alone.

Abstract: The present invention relates to an injectable anthelmintic composition of avermectin and basic albendazole sulfoxide for combating parasites that infest animals. The invention further contemplates a specific method that allows the stable association of avermectin and basic albendazole sulfoxide.

Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.

Abstract: The invention relates to a combination of a pyrimidine derivative and a fatty acid source for use in the treatment of constipation, in particular in the treatment of constipation in patients suffering from GI disorders, neurological disorders, or psychiatric disorders. Advantageously, the combination comprises one or more vitamins or fibres.

Abstract: A therapeutically effective composition for treating Alzheimer's disease includes a pharmaceutically acceptable dosage form comprising melatonin, resveratrol, EGCG, and vitamin B12 combined in a therapeutically effective amount. A combinatorial treatment method for Alzheimer's disease includes administering to a human having Alzheimer's disease a therapeutically effective combination of melatonin, resveratrol, EGCG, and vitamin B12. A method of treating Alzheimer's disease includes administering to a human having Alzheimer's disease a therapeutically effective amount of a pharmaceutically acceptable dosage form comprising melatonin, resveratrol, EGCG, and vitamin B12.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) and astaxanthin in an oral dosage form. The astaxanthin may be derived from a natural or synthetic ester or synthetic diol. The composition may include a mixture of cartilage and salt and boron.

Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) in an oral dosage form.

Abstract: Provided are a pharmaceutical composition including iron oxide nanoparticles for preventing or treating iron deficiency and iron deficiency anemia accompanied thereby, and a preparation method thereof.

Abstract: Here is described a synergystic composition for promoting female fertility, comprising as active ingredients L-carnitine, acetyl L-carnitine; N-acetyl cysteine, and several specific vitamins, aminoacids, antioxidants and micro elements.

Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.

Abstract: Disclosed herein are compositions and methods for the treatment of liver metastases in a subject. The methods include hepatic arterial infusion (HAI) of chimeric antigen receptor modified T cells (CAR-T) which are highly specific for tumor antigens such as carcinoembryonic antigen (CEA). The HAI method is optimized to maximize exposure of the modified cells to the metastatic cells while minimizing exposure to healthy cells. The methods include co-administration of a second therapeutic agent, such as IL-2.

Abstract: It is an object of the present invention to provide a chondrogenesis promoter that is safe and exhibits a chondrogenesis-promoting effect by daily ingestion. It is also an object of the invention to provide a proteoglycan synthesis promoter that exhibits a proteoglycan synthesis-promoting effect by ingestion. Provided are a chondrogenesis promoter and a proteoglycan synthesis promoter each containing a milk-derived basic protein fraction as an active ingredient. Synthesis of proteoglycan and formation of a cartilage can be promoted by oral ingestion of the milk-derived basic protein fraction. A hydrolysate of the milk-derived basic protein fraction also has a similar chondrogenesis-promoting effect.

Abstract: A method for enhancing the therapeutic effect of a stem cell is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell.

Abstract: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia.

Abstract: This document provides methods and materials involved in reducing venous neointimal hyperplasia (VNH) of an arteriovenous fistula (AVF) or graft. For example, methods and materials for using stem cells (e.g., mesenchymal stem cells), extracellular matrix material, or a combination of stem cells and extracellular matrix material to reduce VNH of AVFs or grafts are provided.

Abstract: Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.

Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.

Abstract: The present invention provides a method for preventing or treating a functional gastrointestinal disorder in a subject in need thereof that includes a step of administering a composition, wherein the composition includes an effective amount of Lactobacillus plantarum subsp. plantarum PS128 and a carrier. The present invention further provides a method for preventing or treating visceral hypersensitivity in a subject in need thereof that includes a step of administering a composition, wherein the composition includes an effective amount of Lactobacillus plantarum subsp. plantarum PS128 and a carrier. Moreover, the present invention provides a method for preventing or treating functional abdominal pain, irritable bowel syndrome or constipation in a subject in need thereof that includes a step of administering a composition, wherein the composition includes an effective amount of Lactobacillus plantarum subsp. plantarum PS128 and a carrier.

Abstract: Disclosed herein is an isolated stem cell or population thereof that comprises oncolytic herpes simplex virus (oHSV). Examples of possible stem cells include mesenchymal stem cells (MSC), neuronal stem cells and induced pluripotent stem cells. Various forms of the oHSV are disclosed. Also disclosed are methods of treating brain cancer in a subject by administering the stem cells containing oHSV to the subject to deliver the oHSV to brain cancer cells in the subject. The method is for the treatment of primary brain cancer and secondary metastatic brain cancer.

Abstract: Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. The treatment can also include administration of a monoclonal antibody against epidermal growth factor receptor, for example cetuximab.

Abstract: The present invention is a nutritional supplement made from a combination of natural ingredients. A formulation in accordance with embodiments of the present invention comprises: L-Citrulline, Pine bark extract (such as Pycnogenol®), beetroot, beta alanine, L-Carnitine, branched chain amino acids, CoQ 10, green tea extract, alpha GPC, tart cherry extract, D-Ribose, rhodiola rosea, and hawthorn berry.

Abstract: The present invention is a nutritional supplement made from a combination of natural ingredients. A formulation in accordance with embodiments of the present invention comprises: L-Citrulline, Pine bark extract (such as Pycnogenol®), beetroot, beta alanine, L-Carnitine, branched chain amino acids, CoQ 10, green tea extract, alpha GPC, tart cherry extract, D-Ribose, rhodiola rosea, and shisandra berry.

Abstract: Disclosed are a pharmaceutical composition, a method for preparing the same and use thereof. The pharmaceutical composition consists of total flavonoids of Desmodium Styracifolium as an active ingredient and a pharmaceutically acceptable excipient. The pharmaceutical composition can be formulated in a form of a medicament formulation suitable to administration in clinic, and can be used in preparation of clinic treatment medicaments for treating dampness-heat and urinary stone (stagnation of dampness-heat).

Abstract: The present invention relates to a new composition for use in the treatment of cough comprising, as sole active principles, Plantago lanceolata extract, honey, cane sugar, Thymus sp. extract and optionally Sambucus nigra juice.

Abstract: A formulation comprising a variety of Chinese herbs is disclosed for the treatment of cancer and side effects associated with the treatment of cancer.

Abstract: The present invention concerns a combination comprising the dipeptide L-alanyl-L-glutamine, hyaluronic acid or one of the salts of same and an oat extract, advantageously intended for healing wounds and repairing skin lesions.

Abstract: The present invention relates to compositions and methods for increasing the effectiveness of antibiotics against bacteria, particularly antibiotic resistant bacteria.

Abstract: A polypeptide represented by SEQ ID NO: 1 and a method for treatment of a tumor and another disease associated with abnormal cell proliferation are described. The method includes administering a pharmaceutically-effective amount of the polypeptide to a patient in need thereof.

Abstract: The present disclosure relates to vancomycin-sugar conjugates, its stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. The present disclosure also relates to process of preparation of the vancomycin-sugar conjugates, its stereoisomers, prodrugs, pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases mediated by bacteria.

Abstract: Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.

Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest.

Abstract: A method for forming an immune-tolerant site, and a method for attracting immunosuppressive cells, comprising contacting an agent comprising SEK-1005 (Ser, 3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) and/or fibroblast growth factor (FGF) with a site in the body tissue.

Abstract: Applications of recombined ganoderma lucidum immunoregulation protein (rLZ-8) in preparing drugs for treating tissue fibrosis are provided.

Abstract: The preset invention relates to a new method or composition for treating a gastric ulcer, preventing or treating an infection of H. pylori, particularly multidrug resistant H. pylori, using an antimicrobial peptide, a functional derivate, fragment or variant thereof, wherein the antimicrobial peptide is selected from the group consisting of Epi-1, TPs and combination thereof.

Abstract: An object of the present invention is to provide a means for preventing or treating osteoarthritis. The present invention provides a composition for preventing or treating osteoarthritis, comprising a fish cartilage water extract containing proteoglycans having molecular weights of not less than 1,800,000.

Abstract: Provided herein are animals expressing light-responsive opsin proteins in the basal lateral amygdala of the brain and methods for producing the same wherein illumination of the light-responsive opsin proteins causes anxiety in the animal. Also provided herein are methods for alleviating and inducing anxiety in an animal as well as methods for screening for a compound that alleviates anxiety in an animal.

Abstract: Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, scleraxis-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1?2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1?2 promoter to DNA thereby inhibiting expression of the collagen 1?2 gene in mammalian cells and tissues.

Abstract: A method is provided for treating bowel disease related to the activity of TNF-?, through the administration of a ?-defensin, analog, or derivative. Such a ?-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally. The ?-defensin, analog, or derivative can be selected to additionally inhibit ADAM-10 activity.

Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.

Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.

Abstract: The present invention features methods for treating or ameliorating tissue damage using intravenous administration of compositions (for example, isolated peptide compositions or stem cells expressing such peptides) that include stromal cell derived factor-1 (SDF-1) peptides or mutant SDF-1 peptides that have been mutated to make them resistant to protease digestion, but which retain chemoattractant activity.

Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.